Review



nab paclitaxel  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress nab paclitaxel
    Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and <t>albumin-bound</t> <t>nab-paclitaxel</t> enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]
    Nab Paclitaxel, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/Nab-Paclitaxel/pmc13410306-53-6-18
    Average 94 stars, based on 12 article reviews
    nab paclitaxel - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling"

    Article Title: Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling

    Journal: Cancer Research Communications

    doi: 10.1158/2767-9764.CRC-25-0731

    Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and albumin-bound nab-paclitaxel enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]
    Figure Legend Snippet: Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and albumin-bound nab-paclitaxel enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]

    Techniques Used: Labeling, Staining, Mutagenesis, Fluorescence

    Related Articles

    other:

    Article Title: Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution
    Article Snippet: Thw following drugs were used in this study: Selinexor (HY‐17536); MedChemExpress (Monmouth Junction, NJ, USA), MKT‐077 (HY‐15096); MedChemExpress, CB‐6644 (HY‐114429); MedChemExpress, Carfilzomib (HY‐10455); MedChemExpress, VER‐155008 (HY‐10941); MedChemExpress, Nelfinavir (HY‐15287); MedChemExpress, Nab‐paclitaxel (HY‐P99974); MedChemExpress, Gemcitabine (HY‐17026); MedChemExpress, 5‐Fluorouracil (HY‐90006); MedChemExpress, Oxaliplatin (HY‐17371); MedChemExpress, Irinotecan (HY‐16562); MedChemExpress, Leucovorin (HY‐17556); MedChemExpress, and Docetaxel (HY‐B0011); MedChemExpress.

    Article Title: Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
    Article Snippet: Gemcitabine (LY 188011), Nab-Paclitaxel (HY-P99974), K-80003 (HY-U00458), Copanlisib (HY-15346), Z-FY-CHO (HY-128140) and PD150606 (HY-100529) were purchased from MedChemExpress (Monmouth Junction, New Jersey, USA).

    Article Title: Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling
    Article Snippet: RMC7977 (HY-156498), trametinib (HY-10999), paclitaxel (HY-B0015), nab-paclitaxel (HY-P99974), pictilisib (HY-50094), defactinib (HY-12289), and IAG933 (HY-153811) were purchased from MedChemExpress.

    Pharmaceuticals:

    Article Title: Cellulose microfiber-mediated mesoscale architecture promotes the expansion of patient-derived lung cancer organoids while preserving their malignant characteristics.
    Article Snippet: The crucial role of mesoscale collagen architecture in establishing and expanding patient-derived tumor organoids is well recognized.. However, obtaining sufficient mesoscale collagen bundles from patient cancer tissues is challenging due to the limited availability of such bundles, which depends on the tumor tissue size and digestion efficiency.. In this study, we employed cellulose microfibers (CMFs) with micron-scale thickness to mimic the mesoscale collagen architecture and developed a biomimetic hydrogel termed MF-gel by combining CMFs with microbial transglutaminase-cross-linked gelatin for culturing lung cancer organoids (LCOs).



    Similar Products

    nab paclitaxel  (MedChemExpress)
    94
    MedChemExpress nab paclitaxel
    Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and <t>albumin-bound</t> <t>nab-paclitaxel</t> enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]
    Nab Paclitaxel, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/Nab-Paclitaxel/pmc13410306-53-6-18
    Average 94 stars, based on 1 article reviews
    nab paclitaxel - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    nab paclitaxel  (Bristol Myers)
    86
    Bristol Myers nab paclitaxel
    Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and <t>albumin-bound</t> <t>nab-paclitaxel</t> enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]
    Nab Paclitaxel, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/nab+paclitaxel/pm42303100-38-11-14
    Average 86 stars, based on 1 article reviews
    nab paclitaxel - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    paclitaxel  (MedChemExpress)
    94
    MedChemExpress paclitaxel
    Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and <t>albumin-bound</t> <t>nab-paclitaxel</t> enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]
    Paclitaxel, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/Nab-Paclitaxel/pm41955701-47-0-33
    Average 94 stars, based on 1 article reviews
    paclitaxel - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    nab paclitaxel  (Qilu Pharmaceutical)
    86
    Qilu Pharmaceutical nab paclitaxel
    Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and <t>albumin-bound</t> <t>nab-paclitaxel</t> enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]
    Nab Paclitaxel, supplied by Qilu Pharmaceutical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/nab+paclitaxel/10__1158_slash_2326___6066__cir___25___1194-72-48-49
    Average 86 stars, based on 1 article reviews
    nab paclitaxel - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    nab paclitaxel abraxane  (Bristol Myers)
    86
    Bristol Myers nab paclitaxel abraxane
    Validation <t>of</t> <t>Nab-paclitaxel</t> resistance in established TNBC PDX models Graph showing mean tumor volume (± standard error of the mean, SEM) in PDX-bearing NSG mice treated with nab-paclitaxel compared with untreated controls. Graph created using Prism 8. Statistical analysis was performed using one-way ANOVA. n.s = non-significant ( p > 0.05).
    Nab Paclitaxel Abraxane, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/nab+paclitaxel/pmc12969394-22-0-3
    Average 86 stars, based on 1 article reviews
    nab paclitaxel abraxane - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    nab paclitaxel abraxane  (Celgene)
    86
    Celgene nab paclitaxel abraxane
    PAC cells chemoresponses in 2D and 3D Culture. Percent survival of PAC, HPDE, and CAF cells cultured in 2D or 3D are displayed after treatment with gemcitabine (gem), docetaxel <t>(dtx),</t> <t>nab-paclitaxel</t> (Nab-Ptx), or triptolide (tri) at the concentration of 100 nM or 10 μM (Mean ± SD). All growth assays were done in six replicates. *: p<0.05, **: p<0.01, ***: p<0.001
    Nab Paclitaxel Abraxane, supplied by Celgene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/abraxane/pmc11910381-56-30-33
    Average 86 stars, based on 1 article reviews
    nab paclitaxel abraxane - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    nab paclitaxel  (Selleck Chemicals)
    96
    Selleck Chemicals nab paclitaxel
    PAC cells chemoresponses in 2D and 3D Culture. Percent survival of PAC, HPDE, and CAF cells cultured in 2D or 3D are displayed after treatment with gemcitabine (gem), docetaxel <t>(dtx),</t> <t>nab-paclitaxel</t> (Nab-Ptx), or triptolide (tri) at the concentration of 100 nM or 10 μM (Mean ± SD). All growth assays were done in six replicates. *: p<0.05, **: p<0.01, ***: p<0.001
    Nab Paclitaxel, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nab+paclitaxel/Paclitaxel/pm41826312-298-27-28
    Average 96 stars, based on 1 article reviews
    nab paclitaxel - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and albumin-bound nab-paclitaxel enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]

    Journal: Cancer Research Communications

    Article Title: Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling

    doi: 10.1158/2767-9764.CRC-25-0731

    Figure Lengend Snippet: Upregulated macropinocytosis in RAS inhibitor-resistant cell lines is associated with increased uptake of and sensitivity to albumin-bound paclitaxel compared with free drug. A, Schematic diagram highlighting the differential routes through which free paclitaxel and albumin-bound nab-paclitaxel enter the cell. B, Representative images of macropinosomes labeled with FITC-BSA (green) and nuclear DAPI stain (blue) in indicated parental or MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cells. Images are representative of 10 fields of view analyzed in each of two independent experiments. Scale bars, 20 μm. C, Quantification of median intensity of TMR-BSA fluorescence in indicated MRTX1133- (G12Di-R) or RMC7797-resistant (RASi-R) KRAS -mutant PDAC cell lines plotted relative to matched parental cell line, with each individual data point representing one field containing at least 10 analyzed cells. Data are presented as the mean ± SEM of three independent experiments. ***, ρ < 0.001, and ****, ρ < 0.0001, by the unpaired Student t test, comparing against the parental cell line. D, Representative images of clonogenic growth assays following treatment of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PANC-1 or HPAC cell lines treated with nab-paclitaxel for 12–16 days. E, Relative colony number of matched parental and either MRTX1133- (G12Di-R) or RMC7977-resistant (RASi-R) PDAC cell lines treated with nab-paclitaxel (left) or paclitaxel (right) for 12–16 days. Data are presented as the mean ± SEM of three independent experiments. F, GI 50 values from data plotted in ( E ) for nab-paclitaxel treated lines (top) and paclitaxel treated lines (bottom). *, ρ < 0.05; **, ρ < 0.01; ***, ρ < 0.001, by the unpaired Student t test, comparing against the parental cell line. [ A, Created in BioRender. Robb, R. (2026) https://BioRender.com/nyleshf .]

    Article Snippet: RMC7977 (HY-156498), trametinib (HY-10999), paclitaxel (HY-B0015), nab-paclitaxel (HY-P99974), pictilisib (HY-50094), defactinib (HY-12289), and IAG933 (HY-153811) were purchased from MedChemExpress.

    Techniques: Labeling, Staining, Mutagenesis, Fluorescence

    Validation of Nab-paclitaxel resistance in established TNBC PDX models Graph showing mean tumor volume (± standard error of the mean, SEM) in PDX-bearing NSG mice treated with nab-paclitaxel compared with untreated controls. Graph created using Prism 8. Statistical analysis was performed using one-way ANOVA. n.s = non-significant ( p > 0.05).

    Journal: STAR Protocols

    Article Title: Protocol for establishing a chemoresistant orthotopic triple-negative breast cancer patient-derived xenograft model for preclinical drug testing

    doi: 10.1016/j.xpro.2026.104394

    Figure Lengend Snippet: Validation of Nab-paclitaxel resistance in established TNBC PDX models Graph showing mean tumor volume (± standard error of the mean, SEM) in PDX-bearing NSG mice treated with nab-paclitaxel compared with untreated controls. Graph created using Prism 8. Statistical analysis was performed using one-way ANOVA. n.s = non-significant ( p > 0.05).

    Article Snippet: Nab-paclitaxel (Abraxane) , Bristol Myers Squibb , EU/1/07/428/001.

    Techniques: Biomarker Discovery

    PAC cells chemoresponses in 2D and 3D Culture. Percent survival of PAC, HPDE, and CAF cells cultured in 2D or 3D are displayed after treatment with gemcitabine (gem), docetaxel (dtx), nab-paclitaxel (Nab-Ptx), or triptolide (tri) at the concentration of 100 nM or 10 μM (Mean ± SD). All growth assays were done in six replicates. *: p<0.05, **: p<0.01, ***: p<0.001

    Journal: Journal of chemotherapy (Florence, Italy)

    Article Title: Reversible chemoresistance of pancreatic cancer grown as spheroids

    doi: 10.1080/1120009X.2024.2402177

    Figure Lengend Snippet: PAC cells chemoresponses in 2D and 3D Culture. Percent survival of PAC, HPDE, and CAF cells cultured in 2D or 3D are displayed after treatment with gemcitabine (gem), docetaxel (dtx), nab-paclitaxel (Nab-Ptx), or triptolide (tri) at the concentration of 100 nM or 10 μM (Mean ± SD). All growth assays were done in six replicates. *: p<0.05, **: p<0.01, ***: p<0.001

    Article Snippet: Gemcitabine was purchased from BIOTANG Inc (Waltham, MA); Docetaxel, triptolide, capecitabine, leucovorin, 5- fluorouracil (5-FU), irinotecan, oxaliplatin, mitomycin C, and cisplatin from Sigma; Erlotinib from Selleck Chemicals (Houston, TX); and nab-paclitaxel (Abraxane) from celgene (Summit, NJ).

    Techniques: Cell Culture, Concentration Assay

    Chemoresponses to chemotherapy combinations in 2D or 3D culture. Gemcitabine based chemotherapy (A-C) and 5-FC based chemotherapy (D-G) were evaluated in three PAC cell lines (Mean ± SD). Arrows indicate additive effects by gemcitabine+erlotinib. Arrowheads indicate additive effects of 5-fluorouracil with any of the three other drugs in the FOLFIRINOX (leucovorin, irinotecan, oxaliplatin, or FOLFIRINOX itself). All growth assays were done in six replicates. Gemcitabine (Gem), Nab-paclitaxel (Nab-Ptx), Erlotinib (Erl), F: 5-fluorouracil, L: leucovorin, I: irinotecan, O: oxaliplatin. *: p<0.05, **: p<0.01, ***: p<0.001

    Journal: Journal of chemotherapy (Florence, Italy)

    Article Title: Reversible chemoresistance of pancreatic cancer grown as spheroids

    doi: 10.1080/1120009X.2024.2402177

    Figure Lengend Snippet: Chemoresponses to chemotherapy combinations in 2D or 3D culture. Gemcitabine based chemotherapy (A-C) and 5-FC based chemotherapy (D-G) were evaluated in three PAC cell lines (Mean ± SD). Arrows indicate additive effects by gemcitabine+erlotinib. Arrowheads indicate additive effects of 5-fluorouracil with any of the three other drugs in the FOLFIRINOX (leucovorin, irinotecan, oxaliplatin, or FOLFIRINOX itself). All growth assays were done in six replicates. Gemcitabine (Gem), Nab-paclitaxel (Nab-Ptx), Erlotinib (Erl), F: 5-fluorouracil, L: leucovorin, I: irinotecan, O: oxaliplatin. *: p<0.05, **: p<0.01, ***: p<0.001

    Article Snippet: Gemcitabine was purchased from BIOTANG Inc (Waltham, MA); Docetaxel, triptolide, capecitabine, leucovorin, 5- fluorouracil (5-FU), irinotecan, oxaliplatin, mitomycin C, and cisplatin from Sigma; Erlotinib from Selleck Chemicals (Houston, TX); and nab-paclitaxel (Abraxane) from celgene (Summit, NJ).

    Techniques: